Covid-19 roundup: AlloVir snags IND ap­proval for po­ten­tial T cell ther­a­py; Sanofi and GSK strike 300 mil­lion-dose deal with the EU 

Af­ter snag­ging IND ap­proval for its off-the-shelf virus-spe­cif­ic T cell Covid-19 ther­a­py, AlloVir is now rac­ing to­ward a proof-of-con­cept study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.